Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $340 to $320.
Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $340 to $320.